Current Edition


Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs

Pfizer has agreed to acquire Biohaven Pharmaceuticals for $11.6 billion in a deal that turns an existing alliance on a fast-selling migraine drug into a …

Continue Reading →

Novartis suspends production of two radiopharmaceutical drugs over quality concerns

Dive Brief: Novartis has suspended production of two cancer drugs at plants in Italy and New Jersey due to “potential quality issues” it identified in …

Continue Reading →

FDA panel supports agency push to raise approval bar for certain cancer drugs

The Food and Drug Administration appears ready to raise its approval standards for a well-known class of cancer drugs due to concerns they aren’t helping …

Continue Reading →

Civica targets insulin in effort to produce cheaper drugs

Dive Brief: Civica is making plans to offer three versions of insulin that can be sold at dramatically lower prices than today’s alternatives, targeting a …

Continue Reading →

Amgen partners with Arrakis to develop drugs aimed at RNA

Dive Brief: Amgen will team with Arrakis Therapeutics to develop oral drugs that target and destroy RNA, announcing a deal Tuesday that will pay the Waltham, …

Continue Reading →

Novartis to consider sale or separation of Sandoz business

Under CEO Vas Narasimhan, Novartis has slimmed down what was a sprawling conglomerate spanning prescription and generic drugs, eye care and consumer healthcare. The drugmaker …

Continue Reading →
Drug Patent

4 Drugs Facing Key Patent Expirations and Potential Generic Entry From September 2021–November 2021

A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Yali Friedman at DrugPatentWatch presents a set of an …

Continue Reading →

Blood test to determine best timing to administer drugs

 The team based its research on the fact that the efficacy of drugs changes depending on what time of day they are administered. A team …

Continue Reading →

PhRMA criticizes ICER in latest skirmish over valuing drugs

Industry lobbying group PhRMA on Thursday warned the use of cost-effectiveness estimates like those developed by the Institute for Clinical and Economic Review could force …

Continue Reading →

For Expensive New Drugs, Biopharma Should Make Money-Back Guarantees Mandatory

In a recent paper on “Value-Based Pricing for Drugs”, authors Anna Kaltenboeck and Peter B. Bach of the Memorial Sloan Kettering Cancer Center discuss the …

Continue Reading →